Home Pharmaceuticals Brain Tumor Drugs Market

Brain Tumor Drugs Market Size, Share & Trends Analysis Report By Type (Glioblastoma, Meningioma, Pituitary Tumors, Ependymoma, Medulloblastoma, Others), By Therapy (Chemotherapy Drugs, Immunotherapy Drugs, Cell and Gene Therapy Drugs, Targeted Therapy Drugs, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 29, 2026 | Author: Dhanashri B | Format: | Report Code: SRPH58229DR | Pages: 220

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Brain Tumor Drugs Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Glioblastoma
        1. By Value
      3. Meningioma
        1. By Value
      4. Pituitary Tumors
        1. By Value
      5. Ependymoma
        1. By Value
      6. Medulloblastoma
        1. By Value
      7. Others
        1. By Value
    3. By Therapy
      1. Introduction
        1. Therapy By Value
      2. Chemotherapy Drugs
        1. By Value
      3. Immunotherapy Drugs
        1. By Value
      4. Cell and Gene Therapy Drugs
        1. By Value
      5. Targeted Therapy Drugs
        1. By Value
      6. Others
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Glioblastoma
        1. By Value
      3. Meningioma
        1. By Value
      4. Pituitary Tumors
        1. By Value
      5. Ependymoma
        1. By Value
      6. Medulloblastoma
        1. By Value
      7. Others
        1. By Value
    3. By Therapy
      1. Introduction
        1. Therapy By Value
      2. Chemotherapy Drugs
        1. By Value
      3. Immunotherapy Drugs
        1. By Value
      4. Cell and Gene Therapy Drugs
        1. By Value
      5. Targeted Therapy Drugs
        1. By Value
      6. Others
        1. By Value
    4. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Glioblastoma
          1. By Value
        3. Meningioma
          1. By Value
        4. Pituitary Tumors
          1. By Value
        5. Ependymoma
          1. By Value
        6. Medulloblastoma
          1. By Value
        7. Others
          1. By Value
      2. By Therapy
        1. Introduction
          1. Therapy By Value
        2. Chemotherapy Drugs
          1. By Value
        3. Immunotherapy Drugs
          1. By Value
        4. Cell and Gene Therapy Drugs
          1. By Value
        5. Targeted Therapy Drugs
          1. By Value
        6. Others
          1. By Value
    5. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Glioblastoma
        1. By Value
      3. Meningioma
        1. By Value
      4. Pituitary Tumors
        1. By Value
      5. Ependymoma
        1. By Value
      6. Medulloblastoma
        1. By Value
      7. Others
        1. By Value
    3. By Therapy
      1. Introduction
        1. Therapy By Value
      2. Chemotherapy Drugs
        1. By Value
      3. Immunotherapy Drugs
        1. By Value
      4. Cell and Gene Therapy Drugs
        1. By Value
      5. Targeted Therapy Drugs
        1. By Value
      6. Others
        1. By Value
    4. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Glioblastoma
          1. By Value
        3. Meningioma
          1. By Value
        4. Pituitary Tumors
          1. By Value
        5. Ependymoma
          1. By Value
        6. Medulloblastoma
          1. By Value
        7. Others
          1. By Value
      2. By Therapy
        1. Introduction
          1. Therapy By Value
        2. Chemotherapy Drugs
          1. By Value
        3. Immunotherapy Drugs
          1. By Value
        4. Cell and Gene Therapy Drugs
          1. By Value
        5. Targeted Therapy Drugs
          1. By Value
        6. Others
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Glioblastoma
        1. By Value
      3. Meningioma
        1. By Value
      4. Pituitary Tumors
        1. By Value
      5. Ependymoma
        1. By Value
      6. Medulloblastoma
        1. By Value
      7. Others
        1. By Value
    3. By Therapy
      1. Introduction
        1. Therapy By Value
      2. Chemotherapy Drugs
        1. By Value
      3. Immunotherapy Drugs
        1. By Value
      4. Cell and Gene Therapy Drugs
        1. By Value
      5. Targeted Therapy Drugs
        1. By Value
      6. Others
        1. By Value
    4. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Glioblastoma
          1. By Value
        3. Meningioma
          1. By Value
        4. Pituitary Tumors
          1. By Value
        5. Ependymoma
          1. By Value
        6. Medulloblastoma
          1. By Value
        7. Others
          1. By Value
      2. By Therapy
        1. Introduction
          1. Therapy By Value
        2. Chemotherapy Drugs
          1. By Value
        3. Immunotherapy Drugs
          1. By Value
        4. Cell and Gene Therapy Drugs
          1. By Value
        5. Targeted Therapy Drugs
          1. By Value
        6. Others
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Glioblastoma
        1. By Value
      3. Meningioma
        1. By Value
      4. Pituitary Tumors
        1. By Value
      5. Ependymoma
        1. By Value
      6. Medulloblastoma
        1. By Value
      7. Others
        1. By Value
    3. By Therapy
      1. Introduction
        1. Therapy By Value
      2. Chemotherapy Drugs
        1. By Value
      3. Immunotherapy Drugs
        1. By Value
      4. Cell and Gene Therapy Drugs
        1. By Value
      5. Targeted Therapy Drugs
        1. By Value
      6. Others
        1. By Value
    4. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Glioblastoma
          1. By Value
        3. Meningioma
          1. By Value
        4. Pituitary Tumors
          1. By Value
        5. Ependymoma
          1. By Value
        6. Medulloblastoma
          1. By Value
        7. Others
          1. By Value
      2. By Therapy
        1. Introduction
          1. Therapy By Value
        2. Chemotherapy Drugs
          1. By Value
        3. Immunotherapy Drugs
          1. By Value
        4. Cell and Gene Therapy Drugs
          1. By Value
        5. Targeted Therapy Drugs
          1. By Value
        6. Others
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Glioblastoma
        1. By Value
      3. Meningioma
        1. By Value
      4. Pituitary Tumors
        1. By Value
      5. Ependymoma
        1. By Value
      6. Medulloblastoma
        1. By Value
      7. Others
        1. By Value
    3. By Therapy
      1. Introduction
        1. Therapy By Value
      2. Chemotherapy Drugs
        1. By Value
      3. Immunotherapy Drugs
        1. By Value
      4. Cell and Gene Therapy Drugs
        1. By Value
      5. Targeted Therapy Drugs
        1. By Value
      6. Others
        1. By Value
    4. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Glioblastoma
          1. By Value
        3. Meningioma
          1. By Value
        4. Pituitary Tumors
          1. By Value
        5. Ependymoma
          1. By Value
        6. Medulloblastoma
          1. By Value
        7. Others
          1. By Value
      2. By Therapy
        1. Introduction
          1. Therapy By Value
        2. Chemotherapy Drugs
          1. By Value
        3. Immunotherapy Drugs
          1. By Value
        4. Cell and Gene Therapy Drugs
          1. By Value
        5. Targeted Therapy Drugs
          1. By Value
        6. Others
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Brain Tumor Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Hoffmann-La Roche Ltd. (Switzerland)
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Merck & Co., Inc. (US)
    3. Bristol Myers Squibb (US)
    4. Novartis AG (Switzerland)
    5. Pfizer Inc. (US)
    6. Amgen Inc. (US)
    7. AstraZeneca (UK)
    8. Lilly
    9. Johnson & Johnson (US)
    10. AbbVie Inc. (US)
    11. Bayer AG (Germany)
    12. BeiGene (China)
    13. Astellas Pharma (Japan)
    14. Otsuka Pharmaceutical (Japan)
    15. Eisai (Japan)
    16. Karyopharm Therapeutics (US)
    17. CARsgen Therapeutics (China)
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.